The biotech startups skipping AI for drug discovery

STAT News reports, in the latest installment of its AI Prognosis series, on biotech startups that are choosing not to put artificial intelligence to work on drug discovery itself. According to the outlet, these companies have concluded that drug discovery is not the area where AI delivers the greatest advantage for their work, and they are directing their AI investment toward other parts of the business instead.

The report, published November 4, frames this as a departure from the industry’s dominant narrative, in which AI’s primary promise for biotech has been cast as accelerating the search for new molecules and compounds. STAT News presents these startups as a counterpoint to that assumption, noting that their leadership sees better returns, or more immediate utility, in applying AI to functions beyond the discovery pipeline.

The dispatch does not specify which functions these companies have chosen instead, nor does it name the startups involved in this excerpt of the coverage. It is presented as an observation about a divergence in strategy within the sector, drawn from STAT’s ongoing reporting on how artificial intelligence is being adopted, and in some cases deliberately not adopted, across biotechnology research and development.

The item appears under STAT’s subscriber-focused AI Prognosis banner, which tracks the sector’s evolving relationship with machine learning tools.